Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja C Weisel

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Pageof 10